the pharmaceutical company MSD began to sell fewer drugs in the Russian Federation
The American pharmaceutical company MSD, one of the largest in the world, has reduced its portfolio of drugs sold in Russia by a quarter since the beginning of the Russian invasion of Ukraine. The newspaper “Kommersant” writes about it.
According to the publication, MSD had the most noticeable reduction among representatives of international pharmaceutical manufacturers in Russia. According to Nikolai Bespalov, director of RNC Pharma development, in 2022 MSD supplied Russia with 38 drugs, and in 2023 – 29. He called notable losses the antihypertensive drug “Renitek”, the antidiabetic drugs “Yanuviya” and “Yanumet”, as well as the vaccine from measles, rubella and mumps.
The report of the MSD branch in Russia “MSD Pharmaceuticals” states that the company also stopped production of finished products at the site of the Russian pharmaceutical company “Akrykhin” – there they produced, in particular, “Yanuviya” and “Yanumet”.
In August last year, it became known that MSD would stop supplying Russia with the hepatitis C drug Zepatier. However, the company said that this decision will not affect deliveries planned for 2024.
- After the beginning of the Russian military invasion of Ukraine, several large foreign pharmaceutical companies limited their work in Russia. Yes, Gilead has suspended all non-life-saving drug operations. Pfizer, Bayer, Novartis, MSD, Sanofi and AbbVie continue to supply drugs, but have suspended investment or clinical research. The American pharmaceutical company Eli Lilly has decided to completely withdraw from the Russian market, transferring its business in Russia to its partner in Central and Eastern Europe, Swixx Biopharma.
